CJC-1295 with DAC

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting growth hormone-releasing hormone (GHRH) analog. The DAC modification extends its half-life to 6–8 days by binding to serum albumin, enabling once or twice-weekly dosing instead of the multiple daily injections required by the no-DAC version (Mod GRF 1-29). It produces sustained, non-pulsatile GH elevation.

• Binds to GHRH receptors on anterior pituitary somatotroph cells, stimulating growth hormone synthesis and secretion
• Drug Affinity Complex (DAC) covalently bonds to circulating albumin, extending plasma half-life from minutes to 6–8 days
• Produces sustained, elevated GH and IGF-1 levels rather than natural pulsatile release

• unit: mcg

  low dose: 300

  frequency: 1-2 times per week

  high dose: 1000

  standard dose: 600

  administration route: Subcutaneous (SQ)

• Inject 1–2x weekly, spaced 3–4 days apart. Cycle: 8–12 weeks on, 4 weeks off to preserve receptor sensitivity. Some protocols use continuous dosing under medical supervision.

common: ["Injection site reactions (redness, swelling, itching)","Transient flushing or 'head rush' after injection","Water retention and mild peripheral edema","Headache (more common than with no-DAC version due to sustained GH elevation)"]

warnings: ["May cause sustained GH elevation that does not mimic natural pulsatile release — higher side effect risk vs. no-DAC","Potential for GH receptor downregulation with prolonged continuous use","Do not use in patients with active malignancy or pituitary tumors","Monitor blood glucose — sustained GH elevation may reduce insulin sensitivity"]

long term: ["Possible carpal tunnel symptoms with chronic use","Potential temporary suppression of natural GH rhythm","Risk of insulin resistance with extended high-dose protocols"]

sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(DAC)-NH2

half life: 6–8 days (vs ~30 minutes for no-DAC version)

degradation: Slowly cleared due to albumin binding; DAC protects from enzymatic degradation

molecular weight: 3647.28

tissue specificity: Targets anterior pituitary somatotroph cells via GHRH receptors

• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis.reviewPMID 42395176 ↗